Biovitrum, a Swedish biotech company, acquires Arexis, a privately owned Swedish biotech and pharmaceuticals company, for an undisclosed consideration, from 3i Group Plc, Beijer Investors, Industrifonden, InnovationsKapital, and SEB Företagsinvest.
Vinge acted for Biovitrum AB.
Michael Wigge (responsible partner)
Niclas Bergström (associate)